The GPM6A Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human GPM6A gene in the HeLa epithelial background. This loss-of-function model eliminates endogenous GPM6A protein, enabling unambiguous investigation of its roles in actin cytoskeleton regulation and membrane trafficking. The polyclonal edition creates a diverse allelic pool suited for population-based assays, providing a robust system for functional genomics studies.
HeLa cells are an immortalized cell line originating from a cervical adenocarcinoma of Henrietta Lacks and represent one of the most widely used human cell models in biomedical research. Their epithelial origin and extensive characterization make them an ideal host for studying conserved cellular mechanisms. For a neuronal protein like GPM6A, the non-neuronal HeLa context allows dissection of core functions??such as endocytosis and cytoskeletal dynamics??without interference from neuron-specific differentiation programs.
GPM6A is a four-transmembrane glycoprotein that promotes neurite outgrowth and synaptogenesis through filopodia formation and actin cytoskeleton reorganization. It is activated by neurotrophic factors (NGF, BDNF) and retinoic acid, and signals via Rho GTPases (RhoA, Rac1, Cdc42) and the MAPK pathway to remodel actin. Additionally, GPM6A undergoes clathrin-mediated endocytosis by directly binding clathrin and the AP-2 complex, and it associates with synaptotagmin, connecting it to vesicle trafficking. Thus, GPM6A links extracellular cues to cytoskeletal and endocytic machinery.
In the HeLa knockout model, researchers can probe non-neuronal functions of GPM6A, particularly its involvement in clathrin-mediated endocytosis and actin-based morphogenetic processes that are relevant to cell migration and adhesion. HeLa cells express key components of these pathways, allowing precise dissection of GPM6A-dependent signaling without neuronal background noise. Such studies may yield insights into pathologies like neurodevelopmental disorders, where aberrant neuronal migration and connectivity are hallmarks, or cancer, where cytoskeletal and endocytic deregulation drives invasion.
Applications include western blotting and RT-qPCR to verify knockout, immunofluorescence microscopy to assess actin organization and protein localization, co-immunoprecipitation to detect GPM6A interactions with clathrin or AP-2, and quantitative endocytosis assays using fluorescent transferrin or EGF. The cells are suitable for high-content screening to identify chemical modulators of GPM6A function or compensatory pathways. For further information, please reach out to Ascent Research.
